Follow
Burger Jan
Burger Jan
Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Verified email at mdanderson.org - Homepage
Title
Cited by
Cited by
Year
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, KA Blum, B Grant, ...
New England Journal of Medicine 369 (1), 32-42, 2013
27092013
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ...
New England Journal of Medicine 373 (25), 2425-2437, 2015
16782015
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment
JA Burger, TJ Kipps
Blood 107 (5), 1761-1767, 2006
14772006
Mesenchymal precursor cells in the blood of normal individuals
NJ Zvaifler, L Marinova-Mutafchieva, G Adams, CJ Edwards, J Moss, ...
Arthritis Research & Therapy 2, 1-12, 2000
11292000
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell–derived factor-1
JA Burger, N Tsukada, M Burger, NJ Zvaifler, M Dell'Aquila, TJ Kipps
Blood, The Journal of the American Society of Hematology 96 (8), 2655-2663, 2000
9972000
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
JC Byrd, RR Furman, SE Coutre, JA Burger, KA Blum, M Coleman, ...
Blood, The Journal of the American Society of Hematology 125 (16), 2497-2506, 2015
8382015
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
S Ponader, SS Chen, JJ Buggy, K Balakrishnan, V Gandhi, WG Wierda, ...
Blood, The Journal of the American Society of Hematology 119 (5), 1182-1189, 2012
7572012
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
S O'Brien, RR Furman, SE Coutre, JP Sharman, JA Burger, KA Blum, ...
The lancet oncology 15 (1), 48-58, 2014
7302014
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
JA Burger, P Ghia, A Rosenwald, F Caligaris-Cappio
Blood, The Journal of the American Society of Hematology 114 (16), 3367-3375, 2009
6832009
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
J Hoellenriegel, SA Meadows, M Sivina, WG Wierda, H Kantarjian, ...
Blood, The Journal of the American Society of Hematology 118 (13), 3603-3612, 2011
6652011
Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells
JA Burger, M Burger, TJ Kipps
Blood, The Journal of the American Society of Hematology 94 (11), 3658-3667, 1999
6621999
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers
JA Burger, A Peled
Leukemia 23 (1), 43-52, 2009
5412009
ICOS deficiency is associated with a severe reduction of CXCR5+ CD4 germinal center Th cells
L Bossaller, J Burger, R Draeger, B Grimbacher, R Knoth, A Plebani, ...
The Journal of Immunology 177 (7), 4927-4932, 2006
4972006
Ibrutinib and venetoclax for first-line treatment of CLL
N Jain, M Keating, P Thompson, A Ferrajoli, J Burger, G Borthakur, ...
New England Journal of Medicine 380 (22), 2095-2103, 2019
4832019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
JA Burger, PM Barr, T Robak, C Owen, P Ghia, A Tedeschi, O Bairey, ...
Leukemia 34 (3), 787-798, 2020
4692020
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
F Ravandi, ML Alattar, MR Grunwald, MA Rudek, T Rajkhowa, MA Richie, ...
Blood, The Journal of the American Society of Hematology 121 (23), 4655-4662, 2013
4412013
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
S O’Brien, RR Furman, S Coutre, IW Flinn, JA Burger, K Blum, J Sharman, ...
Blood, The Journal of the American Society of Hematology 131 (17), 1910-1919, 2018
4292018
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
JA Burger, MJ Keating, WG Wierda, E Hartmann, J Hoellenriegel, ...
The Lancet Oncology 15 (10), 1090-1099, 2014
4272014
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion …
AV Kurtova, K Balakrishnan, R Chen, W Ding, S Schnabl, MP Quiroga, ...
Blood, The Journal of the American Society of Hematology 114 (20), 4441-4450, 2009
4222009
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ...
American journal of hematology 94 (12), 1353-1363, 2019
4072019
The system can't perform the operation now. Try again later.
Articles 1–20